Advertisement

Loading...

Orion Nutraceuticals Inc.

ORI.CNCNQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.40
$0.00(0.00%)
Canadian Market opens in 16h 37m

Orion Nutraceuticals Inc. Fundamental Analysis

Orion Nutraceuticals Inc. (ORI.CN) shows weak financial fundamentals with a PE ratio of -126.93, profit margin of 0.00%, and ROE of 8.52%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-77.43

Areas of Concern

ROE8.52%
Operating Margin0.00%
Cash Position0.83%
Current Ratio0.08
We analyze ORI.CN's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 36.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
36.7/100

We analyze ORI.CN's fundamental strength across five key dimensions:

Efficiency Score

Weak

ORI.CN struggles to generate sufficient returns from assets.

ROA > 10%
-94.80%

Valuation Score

Excellent

ORI.CN trades at attractive valuation levels.

PE < 25
-126.93
PEG Ratio < 2
-77.43

Growth Score

Weak

ORI.CN faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

ORI.CN shows balanced financial health with some risks.

Debt/Equity < 1
-0.04
Current Ratio > 1
0.08

Profitability Score

Weak

ORI.CN struggles to sustain strong margins.

ROE > 15%
8.52%
Net Margin ≥ 15%
0.00%
Positive Free Cash Flow
No

Key Financial Metrics

Is ORI.CN Expensive or Cheap?

P/E Ratio

ORI.CN trades at -126.93 times earnings. This suggests potential undervaluation.

-126.93

PEG Ratio

When adjusting for growth, ORI.CN's PEG of -77.43 indicates potential undervaluation.

-77.43

Price to Book

The market values Orion Nutraceuticals Inc. at -10.61 times its book value. This may indicate undervaluation.

-10.61

EV/EBITDA

Enterprise value stands at -126.80 times EBITDA. This is generally considered low.

-126.80

How Well Does ORI.CN Make Money?

Net Profit Margin

For every $100 in sales, Orion Nutraceuticals Inc. keeps $0.00 as profit after all expenses.

0.00%

Operating Margin

Core operations generate 0.00 in profit for every $100 in revenue, before interest and taxes.

0.00%

ROE

Management delivers $8.52 in profit for every $100 of shareholder equity.

8.52%

ROA

Orion Nutraceuticals Inc. generates $-94.80 in profit for every $100 in assets, demonstrating efficient asset deployment.

-94.80%

Following the Money - Real Cash Generation

FCF Per Share

Each share generates $-0.00 in free cash annually.

$-0.00

FCF Yield

ORI.CN converts -0.12% of its market value into free cash.

-0.12%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-126.93

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-77.43

vs 25 benchmark

P/B Ratio

Price to book value ratio

-10.61

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.00

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.04

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.08

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

0.09

vs 25 benchmark

ROA

Return on assets percentage

-0.95

vs 25 benchmark

ROCE

Return on capital employed

0.08

vs 25 benchmark

How ORI.CN Stacks Against Its Sector Peers

MetricORI.CN ValueSector AveragePerformance
P/E Ratio-126.9327.91 Better (Cheaper)
ROE8.52%687.00% Weak
Net Margin0.00%-45285.00% (disorted) Weak
Debt/Equity-0.040.33 Strong (Low Leverage)
Current Ratio0.082795.76 Weak Liquidity
ROA-94.80%-13557.00% (disorted) Weak

ORI.CN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Orion Nutraceuticals Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ